サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1620215

冠動脈ステント市場：タイプ別、材料タイプ別、エンドユーザー別、地域別、2024年～2031年

Coronary Stent Market By Type (Bare-Metal Stents (BMS), Drug-Eluting Stents (DES)), By Material Type (Polymer-Based Stents, Metallic Stents), By End User (Cardiac Centers, Hospitals) And Region For 2024-2031

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
冠動脈ステント市場：タイプ別、材料タイプ別、エンドユーザー別、地域別、2024年～2031年
出版日: 2024年10月06日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

冠動脈ステント市場の評価-2024-2031

冠動脈ステントの世界需要は、主に心血管疾患の有病率の上昇とステント技術の進歩によって、着実に増加しています。心血管疾患は依然として世界の死因の上位を占めており、その要因としては、先進地域でも開発地域でも、座りがちなライフスタイル、不健康な食生活、喫煙、高齢化などが挙げられます。冠動脈疾患の罹患率が上昇するにつれ、効果的な治療オプションに対するニーズも高まり、冠動脈ステント市場を牽引しています。市場規模は2023年に71億1,000万米ドルを突破し、2031年には約138億7,000万米ドルに達します。

薬剤溶出ステントや生体吸収性血管スカフォールドを含むステント技術の革新により、これらのデバイスはより安全で効果的なものとなり、医療界における採用の増加をさらに後押ししています。費用対効果が高く効率的な冠動脈ステントに対する需要の高まりが、2024年から2031年までのCAGR 8.71%での市場の成長を可能にしています。

冠動脈ステント市場定義/概要

冠動脈ステントは、心臓に血液を供給する冠動脈の狭窄や閉塞を治療するために使用される金属製の小さなメッシュチューブです。通常、経皮的冠動脈形成術（PCI）または血管形成術として知られる手技の際に植え込まれます。冠動脈ステントは動脈壁を支えることで血流を回復させ、胸痛や心臓発作、冠動脈疾患（CAD）に伴うその他の合併症のリスクを軽減するように設計されています。冠動脈ステントにはベアメタルステント、薬剤溶出性ステント（DES）、生体吸収性ステントなどいくつかの種類があり、それぞれ安全性、有効性、寿命の点で独自の利点があります。

冠動脈ステントは、ステント技術の進歩、低侵襲手術に対する需要の高まり、CADの有病率の増加などを背景に有望視されています。生体吸収性ステントやナノテクノロジーに基づくステントなどの新たな技術革新は、再狭窄や血栓症などの合併症を減少させることで長期予後を改善すると期待されています。さらに、高齢化が進み、特に新興国地域でヘルスケアへのアクセスが世界的に改善するにつれて、冠動脈ステントに対する需要が高まり、市場に新たな成長機会が生まれると考えられます。

心血管疾患（CVD）の有病率の上昇は冠動脈ステント市場を牽引するか？

心血管疾患（CVD）の有病率の上昇は、冠動脈の閉塞を管理・緩和するための効果的な治療オプションに対するニーズの高まりが主な原因となって、冠動脈ステント市場を大きく牽引しています。WHOによると、心血管系疾患は毎年1,790万人の世界の死亡を引き起こし、CDCの報告によると、冠動脈性心疾患は約1,820万人の米国の成人に影響を及ぼしており、冠動脈ステント留置術の需要は急増しています。このような患者数の増加により、高度で利用しやすいステント・ソリューションが必要とされ、ヘルスケア・システムがCVD関連の罹患率と死亡率の削減を目指しているため、市場の成長が促進されています。

高齢者人口の増加が冠動脈ステント市場に拍車をかけています。加齢は冠動脈疾患の主要な危険因子であるため、高齢者の増加は冠動脈ステントの需要を直接的に増加させる。国連によると、65歳以上の世界人口は2050年までに15億人に達すると予想されており、開発途上地域が最も急速に成長すると見られています。EUでは、経皮的冠動脈インターベンション（PCI）全体の20％近くが75歳以上の患者を対象としており、高齢化とステント治療の増加との間に明確な関連があることを示しています。

高コストは冠動脈ステント市場の成長に影響するか？

冠動脈ステントの高額費用は冠動脈ステント市場の成長に影響を与える可能性があります。ステント治療、特に先進的な薬剤溶出ステントにかかる費用は、患者やヘルスケアシステムにとって法外な負担となる可能性があり、特に予算の制約や医療保険が限られている中低所得国ではその傾向が顕著です。こうした費用は保険料にも影響するため、ステント治療へのアクセスが悪くなり、高齢化と心血管疾患有病率の上昇によって需要が増加しているにもかかわらず、普及率と市場成長が鈍化する可能性があります。

合併症のリスクは冠動脈ステント市場の成長に影響を与える可能性があります。ステント血栓症、再狭窄、出血などの合併症は重大な健康リスクをもたらし、追加処置、医療費の増加、患者の躊躇につながる可能性があります。こうした潜在的な合併症に対する懸念が医療従事者に代替治療の検討を促す可能性があるため、こうしたリスクを最小限に抑えることを目的としたステント技術の進歩にもかかわらず、市場の成長は制限されることになります。

目次

第1章 冠動脈ステントの世界市場：イントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • 検証
  • 一次資料
  • データソース一覧

第4章 冠動脈ステントの世界市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 冠動脈ステントの世界市場：タイプ別

  • 概要
  • ベアメタルステント（BMS）
  • 薬剤溶出ステント（DES）

第6章 冠動脈ステントの世界市場：材料タイプ別

  • 概要
  • ポリマーベースステント
  • 金属ステント

第7章 冠動脈ステントの世界市場：エンドユーザー別

  • 概要
  • 心臓センター
  • 病院

第8章 冠動脈ステントの世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ
    • その他中東とアフリカ

第9章 冠動脈ステントの世界市場：競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略
  • 企業の業界フットプリント
  • 企業の地域別フットプリント
  • エースマトリックス

第10章 企業プロファイル

  • Abbott Laboratories
  • Boston Scientific
  • Medtronic
  • Terumo Corporation
  • B. Braun Melsungen
  • Cook Medical
  • Biosensors International
  • Biotronik, Johnson & Johnson
  • Meril Life Sciences

第11章 主な発展

  • 製品の上市／開発
  • 合併と買収
  • 事業拡大
  • パートナーシップと提携

第12章 付録

  • 関連レポート
目次
Product Code: 10608

Coronary Stent Market Valuation - 2024-2031

The global demand for coronary stents has been steadily increasing, driven primarily by the rising prevalence of cardiovascular diseases and advancements in stent technology. Cardiovascular disease remains a leading cause of death worldwide, with contributing factors such as sedentary lifestyles, unhealthy diets, smoking, and aging populations in developed and developing regions. As the incidence of coronary artery disease rises, so does the need for effective treatment options, propelling the market for coronary stents. The market size surpass USD 7.11 Billion valued in 2023 to reach a valuation of aroundUSD 13.87 Billion by 2031.

Innovations in stent technology, including drug-eluting stents and bioresorbable vascular scaffolds, have made these devices safer and more effective, further supporting their increased adoption in the medical community. The rising demand for cost-effective and efficient coronary stent is enabling the market grow at aCAGR of 8.71% from 2024 to 2031.

Coronary Stent Market: Definition/ Overview

A coronary stent is a small, metal mesh tube used to treat narrowed or blocked coronary arteries, which supply blood to the heart. It is typically implanted during a procedure known as percutaneous coronary intervention (PCI) or angioplasty. Coronary stents are designed to restore blood flow by supporting the artery walls, reducing the risk of chest pain, heart attacks, and other complications associated with coronary artery disease (CAD). There are several types of coronary stents, including bare-metal stents, drug-eluting stents (DES), and bioresorbable stents, each offering unique benefits in terms of safety, efficacy, and longevity.

Coronary stents is promising, driven by advancements in stent technology, growing demand for minimally invasive procedures, and the increasing prevalence of CAD. Emerging innovations, such as bioresorbable and nanotechnology-based stents, are expected to improve long-term outcomes by reducing complications like restenosis and thrombosis. Additionally, as the aging population grows and healthcare access improves globally, particularly in developing regions, the demand for coronary stents is likely to rise, creating new growth opportunities in the market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Drive the Coronary Stent Market?

The rising prevalence of cardiovascular diseases (CVD) is significantly driving the coronary stent market, primarily due to the growing need for effective treatment options to manage and alleviate coronary artery blockages. With cardiovascular diseases causing 17.9 million deaths globally each year, according to the WHO, and coronary heart disease affecting around 18.2 million U.S. adults, as reported by the CDC, the demand for coronary stenting procedures has surged. This increasing patient pool necessitates advanced and accessible stent solutions, driving market growth as healthcare systems aim to reduce CVD-related morbidity and mortality.

The growing elderly population is indeed fueling the coronary stent market. As age is a primary risk factor for coronary artery disease, the rising number of elderly individuals directly increases the demand for coronary stents. According to the United Nations, the global population aged 65 and above is expected to reach 1.5 billion by 2050, with developing regions seeing the fastest growth. In the EU, nearly 20% of all percutaneous coronary interventions (PCIs) target patients aged 75 or older, illustrating a clear link between aging populations and increased stent procedures.

Will the High-Cost impact the Growth of the Coronary Stent Market?

The high cost of coronary stents can impact the growth of the coronary stent market. The expense of stent procedures, particularly for advanced drug-eluting stents, can be prohibitive for patients and healthcare systems, especially in low- and middle-income countries where budget constraints and limited healthcare coverage are prevalent. These costs also impact insurance premiums, making stent procedures less accessible, which can slow the adoption rate and market growth despite the increasing demand driven by aging populations and rising cardiovascular disease prevalence.

The risk of complications can impact the growth of the coronary stent market. Complications such as stent thrombosis, restenosis, and bleeding pose significant health risks, which can lead to additional procedures, increased medical costs, and patient hesitancy. Concerns over these potential complications may prompt healthcare providers to consider alternative treatments, thus limiting the market's growth despite advancements in stent technology aimed at minimizing these risks.

Category-Wise Acumens

Will the Reduced Restenosis Raise the Drug-Eluting Stents (DES) Segment for the Coronary Stent Market?

Drug-Eluting Stents (DES) Segment is dominating the coronary stent market. Reduced restenosis rates are likely to propel the growth of the Drug-Eluting Stents (DES) segment in the coronary stent market. DES is designed to release medication that inhibits cell proliferation, significantly reducing the risk of restenosis compared to bare-metal stents. This improved efficacy in preventing artery re-narrowing makes DES a preferred choice for patients and healthcare providers, driving higher adoption rates and supporting market growth in this segment.

Technological advancements are propelling the drug-eluting stents (DES) segment within the coronary stent market. Innovations such as improved biocompatible polymers, biodegradable stents, and advanced drug coatings have enhanced the safety and effectiveness of DES, reducing complications like restenosis and improving patient outcomes. These advancements make DES an increasingly preferred choice among healthcare providers, driving growth within this segment as they seek safer and more effective solutions for coronary artery disease.

Will the Proven Efficacy Fuel the Metallic Stents Segment for the Coronary Stent Market?

The metallic stents segment is ruling the coronary stent market. The proven efficacy of metallic stents is promoting growth in this segment of the coronary stent market. Metallic stents, particularly drug-eluting and bare-metal stents, have shown reliable results in maintaining vessel patency and reducing the risk of acute complications. Their durability and established clinical success make them a trusted choice for many cardiologists, especially in complex cases, driving continued demand and growth within this segment as they offer consistent and effective treatment for coronary artery disease.

Cost-effectiveness is promoting the metallic stents segment within the coronary stent market. Metallic stents, especially bare-metal stents, offer a more affordable option compared to drug-eluting or biodegradable stents, making them attractive for patients and healthcare systems in cost-sensitive regions. Their durability and relatively lower cost make metallic stents a practical choice for managing coronary artery disease, thus driving demand in regions with budget constraints or limited healthcare funding.

Country/Region-wise Acumens

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Accelerate the North American Region for Coronary Stent Market?

North America's dominance in the coronary stent market. The rising prevalence of cardiovascular diseases (CVD) is likely to accelerate the coronary stent market' in North America. With about 20.1 million adults aged 20 and older currently affected by coronary artery disease (CAD) and an expected increase to 28.5 million by 2040, there is a growing demand for coronary stents. This demand stems from the need for effective treatment options, as coronary stents play a critical role in managing CAD by improving blood flow and reducing the risk of severe cardiac events, thereby driving market growth.

The advanced healthcare infrastructure in North America is accelerating the growth of the coronary stent market. The region's extensive network of around 6,090 hospitals in the U.S. alone enables widespread access to cardiac procedures, with over 1 million coronary stent procedures performed annually. This accessibility, combined with skilled healthcare professionals and advanced medical technologies, ensures timely treatment for cardiovascular diseases, thereby driving demand and growth in the coronary stent market.

Will the Large Patient Pool Expand the Asia Pacific Region for the Coronary Stent Market?

Asia Pacific is rapidly growing in the coronary stent market due to several factors. The large patient pool in the Asia Pacific region is significantly escalating the growth of the coronary stent market. The region accounts for nearly 60% of the global cardiovascular disease burden, as reported by the Asian Pacific Society of Cardiology. Additionally, Japan's aging population, with 27.6% affected by cardiovascular diseases, highlights the demand for coronary interventions. This high prevalence, combined with the growing need for accessible treatment options, drives the expansion of the coronary stent market in Asia Pacific.

The growing disease burden is significantly escalating the coronary stent market in the Asia Pacific region. With China reporting over 330 million patients with cardiovascular diseases and India expecting its coronary artery disease cases to rise from 65.1 million to 75 million by 2030, the demand for coronary stents is increasing. This high prevalence of cardiovascular conditions is driving the need for coronary stent procedures, as healthcare providers seek effective treatments to manage the rising cases and improve patient outcomes across the region.

Competitive Landscape

The coronary stent market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the coronary stent market include:

  • Abbott Laboratories, Boston Scientific, Medtronic, Terumo Corporation, Braun Melsungen, Cook Medical, Biosensors International, Biotronik, Johnson & Johnson, Meril Life Sciences

Latest Developments

  • In April 2021, Abbott announced the launched of coronary imaging platform Ultreon 1.0 Software powered by AI in Europe. The software has been launched with an aim to improve detection of calcium-based blockages and measure vessel diameter during coronary stenting procedures.
  • In February 2021, Cardiovascular Systems Inc established a partnership with Chansu Vascular Technologies, LLC to produce peripheral and coronary drug-coated balloons for use in drug-eluting stents.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL CORONARY STENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL CORONARY STENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CORONARY STENT MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Bare-Metal Stents (BMS)
  • 5.3 Drug-Eluting Stents (DES)

6 GLOBAL CORONARY STENT MARKET, BY MATERIAL TYPE

  • 6.1 Overview
  • 6.2 Polymer-Based Stents
  • 6.3 Metallic Stents

7 GLOBAL CORONARY STENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Cardiac Centers
  • 7.3 Hospitals

8 GLOBAL CORONARY STENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle East and Africa

9 GLOBAL CORONARY STENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Industry Footprint
  • 9.5 Company Regional Footprint
  • 9.6 Ace Matrix

10 COMPANY PROFILES

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Outlook
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus and Strategies
    • 10.1.8 Threat From Competition
    • 10.1.9 Swot Analysis
  • 10.2 Boston Scientific
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Medtronic
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Terumo Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 B. Braun Melsungen
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Cook Medical
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Biosensors International
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Biotronik, Johnson & Johnson
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Meril Life Sciences
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Reports